Marisa Wexler, MS,  senior science writer—

People with Cushing’s syndrome commonly lose weight after the disorder is treated, a new study found. Findings indicate that nearly half of Cushing’s patients who achieve disease remission lose at least 5% of their total body weight in the years following treatment, and nearly a third lose 10% or…

The first participant has been dosed in a Phase 2 clinical trial testing ST-002 in people with Cushing’s syndrome and high blood sugar levels. “ST-002 has the potential to change the treatment landscape for patients who currently have limited therapeutic options,” Manohar Katakam, PhD, CEO of treatment developer Sterotherapeutics,…

Treatment with Isturisa (osilodrostat) was found to be effective for reducing cortisol levels in people with Cushing’s disease and other forms of Cushing’s syndrome, according to data from a real-world study. The study, “Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the…

Cognitive issues are most common in people with Cushing’s disease who have high cortisol levels in the morning, high blood sugar, and a high body mass index (BMI), a study shows. Based on these identified risk factors, researchers devised a mathematical model to help predict the risk of cognitive…

The U.S. Food and Drug Administration (FDA) has approved Isturisa (osilodrostat) to treat adults with all forms of endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative. This marks an expansion of the approved indication for Isturisa, which had previously been cleared only…

  A clinical trial aims to assess the prevalence of Cushing’s syndrome in adults with hard-to-treat high blood pressure. The trial, called MOMENTUM (NCT06829537), plans to recruit 1,000 adults with hypertension (high blood pressure) that remains uncontrolled despite the use of at least three different types of medications designed…

The U.S. Food and Drug Administration (FDA) has accepted an application from Corcept Therapeutics seeking the approval of relacorilant as a treatment for people with endogenous Cushing’s syndrome. A decision from the FDA is now expected by Dec. 30, according to the company. “The FDA’s acceptance of our…

Sterotherapeutics has announced the launch of a Phase 2 clinical trial to test its experimental therapy ST-002 in people with Cushing’s syndrome. “This trial represents a significant step forward in our mission to develop transformative therapies for unmet medical needs,” Manohar Katakam, PhD, CEO of Sterotherapeutics, said in…

In rare cases, Cushing’s syndrome can be caused by tumors that are simultaneously producing two signaling molecules called adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH). Diagnosing Cushing’s in these cases can be complex, leading to delays in treatment and worse outcomes for patients, according to a new report. “Studies…

Differences in the levels of hormones made by the adrenal glands, which sit atop the kidneys, may explain why bone density is less affected in women with Cushing’s disease than in female patients with other forms of Cushing’s syndrome, a new study from researchers in China reports. Their results…